JP2004534787A5 - - Google Patents

Download PDF

Info

Publication number
JP2004534787A5
JP2004534787A5 JP2003501992A JP2003501992A JP2004534787A5 JP 2004534787 A5 JP2004534787 A5 JP 2004534787A5 JP 2003501992 A JP2003501992 A JP 2003501992A JP 2003501992 A JP2003501992 A JP 2003501992A JP 2004534787 A5 JP2004534787 A5 JP 2004534787A5
Authority
JP
Japan
Prior art keywords
alkyl
group
cyclopropyl
optionally
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003501992A
Other languages
English (en)
Japanese (ja)
Other versions
JP4424983B2 (ja
JP2004534787A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/016720 external-priority patent/WO2002098869A2/en
Publication of JP2004534787A publication Critical patent/JP2004534787A/ja
Publication of JP2004534787A5 publication Critical patent/JP2004534787A5/ja
Application granted granted Critical
Publication of JP4424983B2 publication Critical patent/JP4424983B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003501992A 2001-06-05 2002-05-24 １，４−ジ置換ベンゾ−縮合シクロアルキルウレア化合物 Expired - Lifetime JP4424983B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29590901P 2001-06-05 2001-06-05
PCT/US2002/016720 WO2002098869A2 (en) 2001-06-05 2002-05-24 1,4-disubstituted benzo-fused cycloalkyl urea compounds

Publications (3)

Publication Number Publication Date
JP2004534787A JP2004534787A (ja) 2004-11-18
JP2004534787A5 true JP2004534787A5 (https=) 2006-01-05
JP4424983B2 JP4424983B2 (ja) 2010-03-03

Family

ID=23139733

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003501992A Expired - Lifetime JP4424983B2 (ja) 2001-06-05 2002-05-24 １，４−ジ置換ベンゾ−縮合シクロアルキルウレア化合物

Country Status (10)

Country Link
US (1) US6720321B2 (https=)
EP (1) EP1414810B1 (https=)
JP (1) JP4424983B2 (https=)
AT (1) ATE338035T1 (https=)
AU (1) AU2002310156A1 (https=)
CA (1) CA2446193C (https=)
DE (1) DE60214392T2 (https=)
ES (1) ES2269709T3 (https=)
MX (1) MXPA03011006A (https=)
WO (1) WO2002098869A2 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664259B2 (en) * 2000-03-16 2003-12-16 Smithkline Beecham Corporation Il-8 receptor antagonists
WO2003022273A1 (en) * 2001-09-13 2003-03-20 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediated diseases
EP1480973B1 (en) 2002-02-25 2008-02-13 Boehringer Ingelheim Pharmaceuticals Inc. 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
TW200418812A (en) * 2002-10-29 2004-10-01 Smithkline Beecham Corp IL-8 receptor antagonists
RU2366655C2 (ru) * 2003-03-14 2009-09-10 Оно Фармасьютикал Ко., Лтд. Азотсодержащие гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента
WO2005023761A2 (en) 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
US8143404B2 (en) 2004-09-13 2012-03-27 Ono Pharmaceutical Co., Ltd Nitrogenous heterocylic derivative and medicine containing the same as an active ingredient
WO2006035760A1 (ja) * 2004-09-27 2006-04-06 Santen Pharmaceutical Co., Ltd. 皮膚疾患治療剤
WO2006035759A1 (ja) * 2004-09-27 2006-04-06 Santen Pharmaceutical Co., Ltd. 呼吸器疾患治療剤
WO2006043518A1 (ja) * 2004-10-18 2006-04-27 Santen Pharmaceutical Co., Ltd. 神経疾患治療剤
US7741479B2 (en) 2004-12-07 2010-06-22 Locus Pharmaceuticals, Inc. Urea inhibitors of MAP kinases
US7612200B2 (en) 2004-12-07 2009-11-03 Locus Pharmaceuticals, Inc. Inhibitors of protein kinases
CA2644368A1 (en) * 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
US8097626B2 (en) * 2006-04-21 2012-01-17 Glaxosmithkline Llc IL-8 receptor antagonists
PL2009992T3 (pl) * 2006-04-21 2012-11-30 Glaxosmithkline Llc Antagoniści receptora IL-8
CL2007001829A1 (es) * 2006-06-23 2008-01-25 Smithkline Beecham Corp P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
WO2009111207A1 (en) * 2008-03-04 2009-09-11 Merck & Co., Inc. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
EP2432776B1 (en) 2009-05-21 2019-09-11 Universite Laval Methyl sulfanyl pyrimidines useful as antiinflammatories, analgesics, and antiepileptics
MX2012012627A (es) 2010-04-30 2013-05-09 Univ Indiana Res & Tech Corp Proceso para preparar linezolid.
GB201009731D0 (en) * 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
BR112014030940B1 (pt) 2012-06-11 2022-09-06 UCB Biopharma SRL Benzimidazóis que modulam tnf-alfa e composição farmacêutica compreendendo os mesmos
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
MX386697B (es) 2014-01-21 2025-03-19 Janssen Pharmaceutica Nv Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
AU2018352142B2 (en) 2017-10-18 2022-08-25 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
PT3704120T (pt) 2017-11-24 2024-07-03 Jubilant Episcribe Llc Compostos heterocíclicos como inibidores de prmt5
MX2020009517A (es) 2018-03-13 2021-01-20 Jubilant Prodel LLC Compuestos biciclicos como inhibidores de la interaccion/activacio n de pdl/pd-l1.
CN116354891B (zh) * 2022-11-07 2025-01-07 河南省锐达医药科技有限公司 一种萘基苯醚类化合物、其制备方法及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL136768A0 (en) 1997-12-22 2001-06-14 Bayer Ag INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS
ATE529109T1 (de) 1997-12-22 2011-11-15 Bayer Healthcare Llc Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffe
WO1999032463A1 (en) 1997-12-22 1999-07-01 Bayer Corporation INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
ATE278674T1 (de) 1999-03-12 2004-10-15 Boehringer Ingelheim Pharma Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel
JP2002539206A (ja) 1999-03-12 2002-11-19 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症剤としての芳香族複素環化合物
EP1232150B1 (en) * 1999-11-16 2007-10-10 Boehringer Ingelheim Pharmaceuticals Inc. Urea derivatives as anti-inflammatory agents

Similar Documents

Publication Publication Date Title
JP2004534787A5 (https=)
CA2446193A1 (en) 1,4-disubstituted benzo-fused cycloalkyl urea compounds
US6458951B2 (en) Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction
JP4955171B2 (ja) 抗炎症剤としての尿素誘導体
JP3834236B2 (ja) ピラゾロ〔４，３−ｄ〕ピリミジン誘導体
JP2005507367A (ja) １，４−二置換ベンゾ縮合化合物
JP2004531571A5 (https=)
EP1200411B1 (en) Process for synthesis of heteroaryl-substituted urea compounds
JP2005518447A5 (https=)
CA2473634A1 (en) 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
JP2004536845A (ja) サイトカイン媒介疾患の治療方法
JP2004536845A5 (https=)
JP2003514808A5 (https=)
JP2004531571A (ja) サイトカイン生産のインヒビターとしてのカルバメート及びオキサミド化合物
JP2005516936A (ja) Ｎ−ピラジニル−チエニルスルホンアミドおよびケモカイン媒介疾患の治療におけるそれらの使用
US20100137277A1 (en) Pyridine compounds and their use as p2y12 antagonists
JPWO2017014201A1 (ja) 含窒素複素環化合物
US8648099B2 (en) 3-pyridine carboxylic acid hydrazides
JPH05255319A (ja) 新規キノロン誘導体又はその塩、並びに該化合物を含有する抗菌剤
MXPA00010388A (en) Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction